Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer
Open Access
- 30 July 2013
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 356
Abstract
Background: Studies have demonstrated lower rates of breast cancer survival for Black versus White women. Factors implicated include later stages at diagnosis, differences in tumor biology, and lower compliance rates to adjuvant hormone therapy (AHT) among Black women with hormone sensitive breast cancer. We examined factors associated with compliance to AHT among Black and White women with invasive breast cancer. Methods: Women with estrogen receptor positive (ER+), non-metastatic breast cancer were identified by the cancer registry at the University of Chicago Hospital and asked to complete a mail-in survey. Compliance was defined by self-reported adherence to AHT ≥80% at the time of the survey plus medical record verification of persistence (completion of 5 years of AHT). Logistic regression was used to determine factors associated with compliance to AHT. Results: 197 (135 White and 62 Black) women were included in the analysis. 97.4% of patients reported adherence to therapy. 87.4% were found to be persistent to therapy. Overall compliance was 87.7% with no statistically significant racial difference seen (87.9% in White and 87.0% in Black, P = 0.87). For both Black and White women, compliance was strongly associated with both perceived importance of AHT (OR =2.1, 95% CI:1.21-3.68, P = 0.009) and the value placed on their doctor’s opinion about the importance of AHT (OR = 4.80, 95% CI: 2.03-11.4, P < 0.001). Conclusions: In our cohort of Black and White women, perceived importance of AHT and the degree to which they valued their doctor’s opinion correlated with overall compliance. This suggests that Black and White women consider similar factors in their decision to take AHT.Keywords
This publication has 29 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, SpainBritish Journal of Cancer, 2012
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe Lancet, 2011
- Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over timeAnnals of Oncology, 2011
- Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897Journal of Clinical Oncology, 2009
- Early discontinuation of tamoxifenCancer, 2007
- Adherence beliefs among breast cancer patients taking tamoxifenPatient Education and Counseling, 2005
- Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor—Positive Breast CancerJournal of Clinical Oncology, 2004
- Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older WomenJournal of Clinical Oncology, 2001
- Effects of physician communication style on client medication beliefs and adherence with antidepressant treatmentPatient Education and Counseling, 2000